Introduction {#sec1_1}
============

Chronic myeloid leukemia (CML) is a myeloid clonal disease driven by the *bcr-abl* fusion gene, which creates a constitutively active tyrosine kinase. This led to the development of *BCR-ABL1* tyrosine kinase inhibitors (TKIs), which provided long-term remission and improved life expectancy of TKI-treated CML patients \[[@B1]\]. The mechanism of TKI resistance in CML, caused by mutation of the *BCR-ABL1* kinase domain has been extensively investigated \[[@B2]\]. Importantly, the *BCR-ABL1* kinase-independent resistance mechanism due to newly acquired mutations or other genetic aberrations has been reported in a minority of TKI-resistant CML cases \[[@B3]\]. One such mutation was found in *ASXL1*, a histone-binding protein located on chromosome 20q11.2, that disrupts chromatin by enhancing or repressing gene transcription \[[@B4]\]. Then *ABL1* kinase-dependent resistance may promote a change of a patient\'s TKI treatment strategy. As a while, however, it is obscure how much impact the *BCR-ABL1* kinase-independent resistance brings on CML therapy plan.

Originally identified from sequence analysis of myelodysplastic syndrome (MDS) patients \[[@B5]\], mutations in *ASXL1* were a nonspecific genetic abnormality, associated with poor prognosis not only in MDS \[[@B6]\] but also in *bcr-abl*-negative myeloproliferative neoplasms \[[@B6]\]. Mutations in *ASXL1* have been found in the accelerated phase or blast phase \[[@B7]\] and in CML-chronic phase (CP) \[[@B8]\]. Surprisingly, several *ASXL1* mutations have also been reported in healthy people \[[@B9], [@B10], [@B11]\], indicating the pleiotropic nature of *ASXL1*. We present a case of CML-CP resistant to various TKIs and discuss the association between mutations in *ASXL1* and TKI resistance in CML.

Case Presentation {#sec1_2}
=================

A 31-year-old male was diagnosed as CML-CP after an annual occupational health check-up revealed leukocytosis (WBC 187,200/µL), which was subjected to a further examination. The physical examination at his diagnosis revealed giant splenomegaly (palpable 15 cm below costal margin). Blast count was 5.0% in peripheral blood and 7.3% in bone marrow. There was no additional chromosomal abnormality except for t(9;22)(q34;q11.2) by chromosomal analysis. The patient\'s Sokal score was 1.5 indicating high risk, Hasford score was 1,332.4 indicating intermediate risk, EUTOS score was 134 indicating high risk, and ELTS score was 2.0877 indicating intermediate risk. A month after the diagnosis, the patient underwent TKI therapy comprising nilotinib up to 600 mg/day, followed by 600 mg bosutinib, 45 mg ponatinib, and 100 mg dasatinib maximum daily dose. Laboratory data prior to TKI treatment are shown in Table [1](#T1){ref-type="table"}. None of the TKIs exerted a clinical response, except for ponatinib, which yielded a hematological response (Fig. [1](#F1){ref-type="fig"}). No known mutations in the *ABL1* kinase domain were detected after TKI therapy, prompting sequencing analysis. We performed targeted panel sequencing, by using prior-stem cell transplantation sample, which includes 377 genes implicated in myeloid malignancies. This analysis revealed a frameshift mutation in *ASXL1* on chromosome 20q11. The patient underwent a stem cell transplantation with bone marrow donated by an unrelated HLA 7/8-matched (HLA-Cw1 locus mismatched, GVH direction) male from the Japan Marrow Donor Program. Tacrolimus and short-term methotrexate were used for graft-versus-host disease (GVHD) prophylaxis. On the 18th day after transplantation, the patient received neutrophil engraftment followed by reticulocyte engraftment 14 days later and platelet engraftment 22 days later. The patient achieved complete remission, with the bone marrow showing undetectable levels of *BCR-ABL1* mRNA by RT-PCR (International Scale). Despite treatment, the patient died on the 121st day from GVHD and thrombotic microangiopathy, which developed after the patient presented with GVHD.

Discussion {#sec1_3}
==========

Physiologically, ASXL1 encodes a chromatin-binding protein involved in epigenetic regulation \[[@B12]\] by recruiting the polycomb repressive complex 2 (PRC2), a histone methyltransferase, which regulates gene activity by trimethylation of lysine 27 on histone 3 (H3K27me) \[[@B13], [@B14]\]. Mutations in *ASXL1* were originally reported and conferred poor prognosis in MDS \[[@B15]\] and chronic myelomonocytic leukemia (CMMoL) \[[@B5]\]. Frameshift mutations or nonsense mutations in exon 12 of *ASXL1* abrogate protein expression \[[@B12]\] and consequently disrupt its function as a tumor suppressor, often in a variety of hematological malignancies \[[@B8]\]. Mutations in *ASXL1* contribute to oncogenesis in hematopoietic cells, especially leukemogenesis, and promote myeloid transformation through loss of PRC2-mediated gene repression in MDS and CMMoL \[[@B12], [@B16]\].

*ASXL1* mutations are common and associated with disease progression in acute myeloid leukemia (AML) \[[@B17]\] and similarly in CML, where *ASXL1* mutations might be associated with poor prognosis and acute transformation \[[@B5]\]. Variation in prognosis and survival associated with *ASXL1* mutations is seen across studies \[[@B18]\]. *ASXL1* mutations are commonly associated with clonal hematopoiesis in healthy individuals \[[@B9], [@B10], [@B11]\], indicating that *ASXL1* mutation may be a pre-leukemic event in hematopoiesis. Accumulating evidence points to a role for *ASXL1* mutations in leukemogenesis during early hematopoietic events in many hematological malignancies, as described in AML \[[@B18]\] and CML \[[@B19], [@B20]\]. In the latter case, mutations in *ASXL1* occur early in CML stem cells, prior to *bcr-abl* translocation stage \[[@B19]\], as these cells clonally evolve \[[@B20]\]. This is considered an intrinsic event, rather than a *bcr-abl* fusion, which occurs after myeloid lineage differentiation \[[@B20]\].

In the two-hit model of AML development, class I mutation confers a proliferative or survival advantage, and class II mutations result in impaired myeloid differentiation as a secondary event \[[@B21]\]. Class II mutations in *ASXL1* lead to its loss of function, impairing granulomonocytic differentiation in early human hematopoietic progenitors and contributing to leukemogenesis. Indeed, silencing of *ASXL1* impairs the granulomonocytic lineage potential of human CD34^+^ progenitor cells by altering its gene expression profile, but not proliferation and apoptosis \[[@B11], [@B14]\]. Alternatively, *ASXL1* mutations might enhance other leukemogenesis pathways via other mechanisms, including epigenetic regulation.

*ASXL1* plays a key role in epigenetic regulation of gene expression through methylation of histone H3K27, and disruption of *ASXL1* drives myeloid malignancies \[[@B22]\]. Also, *ASXL1* mutations may affect epigenetic regulation by inhibiting ubiquitination of lysine 119 at histone H2A (H2AK119). This may contribute to leukemogenesis though this remains to be proven \[[@B23]\]. Thus, even though a molecular mechanism for TKI resistance in *ASXL1* mutation in CML has remained obscure, epigenetic modulation is a plausible mode of CML disease progression.

*ASXL1* mutations occur early in CML stem cells, prior to *bcr-abl* translocation stage, and therefore, there might not be a high risk of treatment failure following TKI therapy \[[@B20]\]. The patient received hematopoietic stem cell transplantation and went into remission. This optimal response could have been prolonged without TKI maintenance therapy. Taken together, *ASXL1* mutation might follow the HSCT trait as observed in this CML-CP case, which does not progress for years.

Conclusions {#sec1_4}
===========

Whole exome sequence facilitated a clinical decision in this patient who went into remission. Though the clinical impact of *ASXL1* for CML is still under investigation, mutated *ASXL1* possibly explain the TKI resistance mechanism. This case illustrated the necessity of HSCT in *ASXL1* mutation-associated TKI-resistant CML-CP. In future, a discussion of CML with mutated *ASXL1* will facilitate treatment options.
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![The patient\'s clinical course. Nilotinib administration had an adverse effect on white blood cell and platelets, but did not diminish the *bcr-abl* fusion gene. The switch to bosutinib and dasatinib therapy did not change the response. The patient responded only to ponatinib treatment, which achieved a hematological response with 18% of *bcr-abl1* FISH. However, no durable response was available. Hematopoietic stem cell transplantation yielded a molecular response without detection of major *BCR-ABL1* mRNA by RT-PCR. The patient died of transplantation-related mortality, GVHD and TMA on the 121st day after transplantation. FISH, fluorescence in situ hybridization; GVHD, graft-versus-host disease; HSCT, hematopoietic stem cell transplantation; PLT, platelet; TMA, thrombotic microangiopathy; WBC, white blood cells.](cro-0013-0449-g01){#F1}

###### 

Laboratory data before tyrosine kinase inhibitor treatment

  ------------- ------------ --------
  WBC           125,200      /µL
   Stab.        11.5         \%
   Seg.         31.0         \%
   Lym.         3.5          \%
   Mono.        0.0          \%
   Eos.         6.0          \%
   Baso.        6.5          \%
   Blast        6.5          \%
   Promyelo.    1.0          \%
   Myelo.       26.5         \%
   Metamyelo.   7.5          \%
  RBC           327×10^4^    /µL
  Hb            9.3          g/dL
  Hct           30.4         \%
  MCV           93.0         fL
  MCHC          30.6         \%
  PLT           51.0×10^4^   /µL
  CRP           1.20         mg/dL
  TP            6.0          g/dL
  Alb           4.1          g/dL
  BUN           15.2         mg/dL
  Cr            0.68         mg/dL
  UA            6.2          mg/dL
  T-Bil         0.6          mg/dL
  GOT           14           U/L
  GPT           17           U/L
  ALP           235          U/L
  γ-GTP         28           U/L
  CPK           12           U/L
  CHE           181          U/L
  LDH           601          U/L
  Na            140          mmol/L
  K             4.5          mmol/L
  Cl            105          mmol/L
  PT            70           \%
  PT-INR        1.17         
  APTT          46.5         s
  FIB           311          mg/dL
  ATIII         72           \%
  FDP           3            µg/mL
  D-dimer       1.0          µg/mL
  ------------- ------------ --------
